Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis

3

4 Yiran Zhang^{1,2*}, Hanyang Guan^{1*}, Shijin Liu^{1*}, Haoquan Li¹, Zili Bian¹, Jiashuai He¹, Zhan Zhao¹,

5 Shenghui Qiu¹, Tianmu Mo¹, Xiangwei Zhang¹, Zuyang Chen¹, Hui Ding¹, Xiaoxu Zhao¹, Liang

- 6 Wang^{3#}, Yunlong Pan^{1,4#}, Jinghua Pan^{1#}
- 7
- Department of General Surgery, The First Affiliated Hospital of Jinan University, 510632,
 Guangzhou, Guangdong, P. R. China
- Department of Body Gamma Knife, The First Affiliated Hospital of Jinan University, 510632,
 Guangzhou, Guangdong, P. R. China
- Department of Oncology, The First Affiliated Hospital of Jinan University, 510632, Guangzhou,
 Guangdong, P. R. China
- 14 4. MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein
- 15 Research of Guangdong Higher Education Institutes. Institute of Life and Health Engineering, Jinan
- 16 University, Guangzhou, China.
- 17
- 18 *These authors contributed equally
- 19
- 20 Running title: Combined SBRT and Immunotherapy in pMMR mCRC.
- 21

²² ***Corresponding author:**

Jinghua Pan, Department of General Surgery, The First Affiliated Hospital of Jinan University,
 510632, Guangzhou, Guangdong, P. R. China; E-mail: huajanve@foxmail.com

Yunlong Pan: Department of General Surgery, The First Affiliated Hospital of Jinan University,
 510632, Guangzhou, Guangdong, P. R. China; E-mail: tpanyl@jnu.edu.cn

- 27 Liang Wang: Department of Oncology, The First Affiliated Hospital of Jinan University, 510632,
- 28 Guangzhou, Guangdong, P. R. China. E-mail: wangliang@jnu.edu.cn.

29 30

- 31 **Conflict of interest**: The authors disclosed no potential conflicts of interest.
- 32
- 33
- 34
- 35
- 36
- 37

- 39
- 40
- 41
- 42

43 Abstract

| 44 | An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients |
|----|---|
| 45 | with MSS and pMMR mCRC often face great challenges. In this phase II trial, patients received |
| 46 | Gamma Knife SBRT combined with Tislelizumab . P Biomarker analysis was performed pre- and |
| 47 | post-treatment . From November 2022 to July 2024, 13 of 20 patients achieved PR, 6 achieved SD. |
| 48 | mPFS was 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse events |
| 49 | included nausea (65%), anemia (55%), and fatigue (45%). For patients who had not responded to |
| 50 | first and second-line therapies, the combo of Gamma Knife SBRT and tislelizumab showed high |
| 51 | efficacy and reasonable safety. Significant post-radiotherapy improvements in the tumor's |
| 52 | immunosuppressive microenvironment. These results imply that patients with pMMR/MSS/MSI-L |
| 53 | mCRC who were unresponsive to the first and second-line chemotherapy, Gamma Knife SBRT with |
| 54 | tislelizumab provides a safe and powerful later-line treatment alternative. |
| | |

55

Keywords: Gamma Knife Stereotactic body radiation therapy; mismatch repair-proficient;
 tislelizumab; Metastatic colorectal cancer; Immune checkpoint inhibitors; PD-L1.

58

59 Statement of significance

This study offers a safe and powerful option for pMMR/MSS/MSI-L mCRC patients fail to first and second-line chemotherapy. And discover Gamma Knife SBRT contributed to potentially converting the suppressive "cold" tumor immune microenvironment into an activated "hot" microenvironment conducive to immunotherapy efficacy in pMMR CRC.

64

66 Introduction

| 67 | Colorectal cancer continues to represent a significant threat to life. As reported in the 2020 Global |
|----|--|
| 68 | Cancer Statistics, colorectal cancer accounts for 10% of all cancer cases, ranking third in incidence, |
| 69 | while its mortality rate is 9.4%, second only to lung cancer (1,2). Especially, 20% of newly diagnosed |
| 70 | colorectal cancer patients present show metastases, and 40% have recurrence and metastases after |
| 71 | local treatment (3). The FOLFOX/FOLFIRI chemotherapy regimen, which comprises oxaliplatin, |
| 72 | 5-fluorouracil, and irinotecan is the mainstay of clinical treatment for metastatic colorectal cancer |
| 73 | (mCRC). For patients harboring wild-type RAS and BRAF, the addition of the epidermal growth factor |
| 74 | receptor (EGFR) inhibitor cetuximab is recommended(4,5). For patients with RAS mutations, the |
| 75 | anti-angiogenic agent bevacizumab is advised. Nevertheless, RAS-mutant patients exhibit poorer |
| 76 | prognoses and shorter survival times compared to their wild-type counterparts (6,7). The efficacy of |
| 77 | chemotherapy in combination with targeted therapy remains suboptimal (7). |

78

79 The development of immune checkpoint inhibitors (ICIs) transforms cancer immunotherapy (8). 80 Particularly CRCs with mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) 81 show a strong response to ICIs (9). But most CRC cases are either microsatellite-stable/low 82 microsatellite instability (MSS/MSI-L) or mismatch repair-profile (pMMR), which reduces the efficacy of immunotherapy in a significant number of mCRC patients (9). Chemotherapeutic agents can 83 84 cause immunogenic cell death in tumors, thus coordinating with ICIs improves anti-tumor efficacy 85 (10). Additionally, anti-angiogenic therapies targeting VEGFR facilitate the normalization of tumor 86 vasculature and promote immune cell infiltration, subsequently amplifying immune-mediated tumor 87 eradication (11). Clinical studies, however, have revealed that t combining mFOLFOX6 or other

chemotherapy regimens with anti-VEGF, anti-EGFR, and ICIs does not produce better clinical
outcomes in mCRC (12,13). Consequently, identifying alternative strategies to augment the efficacy
of immunotherapy remains a pivotal objective in the field of cancer immunotherapy in
pMMR/MSS/MSI-L mCRC.

92

93 Stereotactic body radiation therapy (SBRT), effectively targets and eradicates tumor cells with 94 high-dose radiation (14). Although traditional radiotherapy is sometimes linked with 95 immunosuppressive effects (15), SBRT's exact targeting can expose tumor neoantigens, mobilize 96 and activate immune cells, increase their infiltration into the tumor, and improve the tumor immune 97 microenvironment (16,17). The Gamma Knife is a principal modality in SBRT, employing gamma rays generated by cobalt-60 to deliver a single, high-dose focused irradiation to the target lesion. The 98 99 Gamma Knife provides several benefits over conventional radiotherapy, including hiexact 100 stereotactic targeting, increased delivery dose to the lesion, prevention of accelerated repopulation 101 of tumor cells, and better local control rates of tumors(18). Our team firstly observed a case with 102 pMMR-type mCRC who exhibited local recurrence and distant metastasis following first-line and 103 second-line chemotherapy combined with targeted therapy(19). After undergoing gamma knife SBRT 104 followed by tislelizumab treatment, intrahepatic metastatic lesions were reduced and stabilized, the 105 patient showed a partial response (PR) with notable reduction of recurrent lesions in the rectal wall 106 and stabilization of intrahepatic metastases, so extending the progression-free survival (PFS) 107 exceeded beyond 3 months (19). These findings suggest that Gamma Knife SBRT might improve 108 ICBs sensitivity in mCRC.

109

The results of a phase II clinical trial assessing the combination of Gamma Knife SBRT combined with tislelizumab as a later-line therapy in patients with pMMR/MSS/MSI-L mCRC are presented in this report together with safety and efficacy. NanoString assay for transcriptome analysis was employed to elucidate changes in the tumor immune microenvironment during the combined treatment, offering insights into the therapeutic potential and mechanistic underpinnings of this integrated approach.

116

117 **Results**

118 Patients

In this clinical trial, twenty patients with pMMR/MSS/MSI-L tumors refractory to first or second-line
treatment were enrolled. The cohort comprised 15 males and 5 females, with ages ranging from 47
to 77 years. Predominantly, the primary tumors were located in the left colon and rectum (17/20,
85%), with the liver being the most common site of metastasis, followed by the lung (3/20)(Table 1).
Flowchart of therapeutic regimen and flow diagram of enrolled participants in the study were shown
in Figure 1A and Figure 1B.

125

Molecular profiling revealed RAS mutations in 11 patients (55%), with 5 exhibiting KRAS mutations and 6 presenting NRAS mutations. PD-L1 expression was assessed in 18 patients, 12 (60%) patients had combined positive score (CPS) \leq 1. Tumor mutation burden (TMB) data were available for 8 patients, with a median TMB of 4.62 mutations/Mb (IQR 3.08-8.97). Notably, only one patient exhibited a TMB > 10 mutations/Mb (**Table 1**).

131

| Characteristics | Patients (n=20) |
|--|------------------|
| Age, years, median (IQR), n (%) | 60 (56-65) |
| <60 | 8 (40%) |
| ≥60 | 12 (60%) |
| Sex, n(%) | |
| Male | 15 (75%) |
| Female | 5 (25%) |
| ECOG performance status, n (%) | |
| 0 | 12 (60%) |
| 1 | 8 (40%) |
| Primary tumor location, n (%) | |
| Left colon and rectum | 17 (85%) |
| Right colon | 3 (15%) |
| Number of metastatic organs ^a , n (%) | |
| 1 | 14 (70%) |
| ≥2 | 6 (30%) |
| Metastatic organ, n (%) | |
| Liver | 14 (70%) |
| Lung | 7 (35%) |
| Lymph node | 2 (10%) |
| Other | 3 (15%) |
| Ras mutation type, n (%) | |
| KRAS | 5 (25%) |
| NRAS | 6 (30%) |
| Other | 9 (45%) |
| PD-L1 expression, CPS, n (%) | |
| CPS≤1 | 12 (60%) |
| CPS > 1 | 6 (30%) |
| Unknown | 2 (10%) |
| TMB (mut/Mb), median (IQR), n (%) | 4.62 (3.08-8.97) |
| TMB<5 | 4 (20%) |
| TMB≥5, ≤10 | 3 (15%) |
| TMB>10 | 1 (5%) |
| Unknown | 12 (60%) |
| | |

Abbreviations: CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; TMB, tumor mutation burden.

> ^aMultiple answers allowed. Table 1: Baseline demographic and clinical characteristics.

132

133 Efficacy

134 In our cohort of 20 patients meeting inclusion criteria, 13 (65%) achieved a partial response (PR), 135 and 6 (35%) maintained stable disease (SD), resulting in a robust disease control rate (DCR) of 95% 136 (Table 2). Patients with liver metastases achieved 92.9% DCR, and patients with metastases in non-liver locations notably achieved a remarkable 100% DCR, only 1 patient with liver metastases 137 138 experienced disease progression (PD) (Figure 2A), As of the data cutoff date, 7 patients remained 139 on maintenance treatment, and 1 patient underwent surgery due to disease progression (Figure 2A). 140 Remarkably, 3 patients refractory to first-line treatment responded to SBRT combined with 141 tislelizumab, achieving rapid regression to NED status, with durations ranging from 6 to 18 months 142 before progression. Encouragingly, 1 patient remains in a state of NED, under ongoing monitoring

143 (**Figure 2A**).

| | All patients (N = 20) | Liver metastasis (N = 14) | Other metastasis (N = 6) |
|---------------------------------|-----------------------|---------------------------|--------------------------|
| Best overall response | | | |
| Complete response (CR), n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Partial response (PR), n (%) | 13 (65%) | 8 (57%) | 5 (83%) |
| Stable disease (SD), n (%) | 6 (30%) | 5 (36%) | 1 (17%) |
| Progressive disease (PD), n (%) | 1 (10%) | 1 (7%) | 0 (0%) |
| ORR, n (%, 95% CI) | 13 (65%, 40.8-84.6%) | 8 (57.1%, 28.9-82.3%) | 5(83.3%, 35.9-99.6%) |
| DCR, n (%, 95% CI) | 19 (95%, 75.1-99.9%) | 13 (92.9%, 66.1-99.8%) | 6(100%, 54.1-100%) |

Abbreviations: ORR, objective response rate; DCR, disease control rate.

Table 2: Efficacy outcomes.

144

| 145 | Most patients exhibited favorable survival outcomes throughout the treatment (Figure 2B), and |
|-----|--|
| 146 | median progression-free survival (PFS) was 10.7 months (95% CI, 6.4, 15.0) (Figure 2C). |
| 147 | Additionally, a comparative survival analysis included 23 patients who underwent first and |
| 148 | second-line treatment and Gamma Knife SBRT without immunotherapy, revealing a median PFS of |
| 149 | 6.7 months (95% CI, 5.6, 7.0), this data shown Gamma Knife SBRT combined with tislelizumab as |
| 150 | later-line treatment prolong PFS in mCRC (Log-rank test = 5.638, P = 0.0176) (Figure 2D). These |
| 151 | findings suggest Gamma Knife SBRT combined with tislelizumab can effectively inhibiting mCRC |
| 152 | progression. |
| 153 | |
| 154 | In light of the abscopal effect of radiotherapy, we extended our observations beyond the lesions |
| 155 | directly targeted by stereotactic radiotherapy to include non-irradiated lesions. Imaging examinations |
| 156 | revealed significant tumor regression in both the irradiated target lesions (Figure 2E, F) and the |
| 157 | non-irradiated lesions (Figure 2E, G) following Gamma Knife SBRT combined with tislelizumab. |
| 158 | These findings suggest that SBRT not only impacts the irradiated lesions but also sensitize distant |
| 159 | metastatic sites for ICBs through the abscopal effect, thereby enhancing the systemic antitumor |
| 160 | response when combined with immunotherapy. |

161

162 Safety

All 20 enrolled patients received the assigned treatment regimen, with safety assessments conducted every three treatment cycles. Treatment-related adverse events (TRAEs) and

immune-related adverse events are summarized in **Table 3.** Predominantly, patients experienced mild to moderate adverse events, with the most common being nausea (65%), anemia (55%), electrolyte disturbances (55%), fatigue (45%), and anorexia (35%). Notably, only two patients experienced grade 3 events of increased blood bilirubin, while no grade 4 adverse events were

169 reported throughout the study period.

| TEAEs, n (%) | Patient (N=20) | | | | |
|---------------------------|----------------|---------|---------|---------|-----------|
| | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Any grade |
| Anemia | 9 (45%) | 2 (10%) | 0 | 0 | 11 (55%) |
| Neutropenia | 1 (5%) | 0 | 0 | 0 | 1 (5%) |
| Nausea | 10 (50%) | 3 (15%) | 0 | 0 | 13 (65%) |
| Poor appetite | 3 (15%) | 4 (20%) | 0 | 0 | 7 (35%) |
| Electrolyte disturbance | 7 (35%) | 2 (10%) | 0 | 0 | 11 (55%) |
| Hand-foot syndrome | 0 | 0 | 0 | 0 | 0 |
| Leukocytopenia | 2 (10%) | 0 | 0 | 0 | 2 (10%) |
| Aspartate transaminase | | | | | |
| increased | 2 (10%) | 2 (10%) | 0 | 0 | 4 (20%) |
| Lipase increased | 0 | 0 | 0 | 0 | 0 |
| Proteinuria | 0 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 2 (10%) | 2 (10%) | 0 | 0 | 4 (20%) |
| Vomiting | 1 (5%) | 3 (15%) | 0 | 0 | 4 (20%) |
| Hypothyroidism | 0 | 0 | 0 | 0 | 0 |
| Triglycerides increased | 0 | 0 | 0 | 0 | 0 |
| Fatigue | 6 (30%) | 3 (15%) | 0 | 0 | 9 (45%) |
| Blood bilirubin increased | 0 | 0 | 2 (10%) | 0 | 2 (10%) |
| Alanine transaminase | | | | | |
| increased | 2 (10%) | 1 (5%) | 0 | 0 | 3 (15%) |
| Peripheral neurotoxicity | 0 | 0 | 0 | 0 | 0 |
| Hoarseness | 0 | 0 | 0 | 0 | 0 |
| Rash | 4 (20%) | 0 | 0 | 0 | 4 (20%) |
| Thyroiditis | 0 (0%) | 0 | 0 | 0 | 0 |
| Diarrhea | 1 (5%) | 0 | 0 | 0 | 1 (5%) |
| Troponin increased | 0 | 0 | 0 | 0 | 0 |
| Fever | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase | | | | | |
| increased | 0 | 0 | 0 | 0 | 0 |
| Amylase increased | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | 0 | 0 | 0 | 0 |

Table 3: Treatment-emergent adverse events (TEAEs) since the initiation of protocol-specified treatment

170

| 171 | Identification of differentially expressed genes between responder and non-response groups |
|-----|---|
| 172 | To elucidate the impact of the tumor immune microenvironment on combination therapy outcomes, |
| 173 | we employed NanoString assay for transcriptome analysis of tumor samples obtained from 16 |
| 174 | enrolled patients before and after treatment, totaling 32 samples (Figure 3A). Patients were stratified |
| 175 | into r responder (PR) and non-responder (non-PR) groups based on treatment outcomes. Gene |
| 176 | expression differential analysis between pre- and post-treatment samples within each group |
| 177 | identified significant alterations, detailed in the Supplementary Data and illustrated in Figure 3B. |
| 178 | |
| 179 | Our findings highlighted notable up-regulation of key genes involved in antigen presentation (CD40, |
| 180 | TNFSF18, TNFSF4), immune checkpoint modulation (PDCD1LG2, CD274, IDO1, VTCN1), and T |
| 181 | cell activation pathways (TNFRSF9, CD28, ICOS, CD40LG, CD2, GZMK, ENTPD1, ITGAE) in the |
| 182 | responder group. Additionally, a diverse array of chemokine family genes (IL2, IL4, IL17A, CCR2, |
| 183 | CCL22) showed enhanced expression in PR group (Figure 3B). Furthermore, immune cell |
| 184 | abundance analysis based on 11 predefined immune cell types revealed significantly elevated levels |
| 185 | in the PR group compared to non-PR. included T cells, B cells, mast cells, macrophages, Dendritic |
| 186 | Cell (DC), Cytotoxic cells, NK CD56 cell, CD8 T cell, CD45 cell, Th1 cells and NK cell (Figure 3C). |
| 187 | This heightened immune activation in responders encompassed robust antigen presentation, T cell |
| 188 | activation, and co-stimulation processes crucial for effective immune-mediated tumor control. |
| 189 | |

190 Following the combination of stereotactic radiotherapy and immunotherapy, a striking reduction in

liver metastasis target lesions was observed in two patients compared to baseline To elucidate these findings, we conducted CD8 and PD-L1 immunohistochemical staining on liver metastasis biopsy specimens from one patient pre- and post-treatment (**Fig 3D-E**). The analysis revealed increased infiltration of T cells and improved immune microenvironment following treatment, aligning with our prior analytical findings.

196

197 Additional immune signatures analysis in predicting tumor response

We conducted gene expression analysis based on 12 predefined gene sets associated with immunotherapy and prognosis (**Figure 4A**). Notably, samples from the responder group exhibited higher expression of immune activation related genes compared to the non-responder group, include effector T cells (T-eff), T cell-Inflamed, IFN-γ, cytotoxic, Cytolytic activity score (CYT), chemokines, angiogenesis (AG), APC co-stimulation (APC co-sti), inflammation promoting (Inflam-pro), T cell co-stimulation (T cell co-sti), parainflammation (parainflam) and tumor-infiltrating lymphocytes (TIL)

204 (**Figure 4A**).

205

Further compared the related-signature score, we found the responders had higher APC and T cell co-stimulation signature scores compared with the non-responder group (**Figure 4B**). Moreover, the responders had higher T cell-Inflamed, inflammation promoting and parainflammation signature scores compared with the non-responder group (**Figure 4C**). Additionally, increased expression of effector T cell, cytotoxicity, IFN-γ production, and cytolytic activity and TIL signature scores compared with the non-responder group (**Figure 4D**).

212

213 Further functional insights into differential gene expression between responder and non-responder 214 groups were gained through gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and 215 Genomes (KEGG) pathway analyses. GO analysis highlighted enrichment in cytokine and 216 chemokine receptor activities, alongside increased T cell and leukocyte proliferation and activation levels in responders (Supplementary Fig 1A). Correspondingly, KEGG analysis underscored 217 218 enrichment in pathways involving antigen processing and presentation, T cell receptor signaling, 219 chemokine interactions, and cytokine signaling (Supplementary Fig 1B). Notably, these results 220 indicated responders after combination of Gamma Knife SBRT and tislelizumab treatment will 221 enhancing tumor antigen presentation and T cell mediated immune response in pMMR/MSS/MSI-L 222 mCRC.

223

Analysis on differential expression genes before and after treatment in the responders.

225 To unravel the mechanisms driving tumor regression in the responder cohort, we conducted 226 comprehensive gene expression analysis before and after treatment, focusing on 7 gene groups 227 known for their potential inhibitory effects on immunotherapy. Post-treatment analysis revealed 228 significant reductions in exhausted T cells, Th2 cells, and Treg cells, indicative of a favorable shift 229 away from a suppressive immune microenvironment (Figure 5A). Tumor resistance mechanisms, 230 such as fibrosis and angiogenesis, play pivotal roles in limiting therapeutic efficacy(20,21). Initially, 231 evaluation of immunotherapy-related gene groups in partial responders versus non-responders 232 highlighted significantly higher angiogenesis scores in the former, albeit with no significantly 233 difference (Figure 5B). Recognizing potential biases from pooling samples pre- and post-treatment, we conducted separate analyses within the responder group, expanding our gene set to include 234

fibrosis-related genes. The findings underscored substantial inhibition of both angiogenesis and fibrosis within the tumor microenvironment following SBRT, targeted therapy, and immunotherapy (**Figure 5C**).

238

Further stratified analysis of non-responder samples before and after treatment revealed no 239 240 significant alterations expression levels in the of immunosuppression-related or 241 angiogenesis/fibrosis-related gene sets (Supplementary Fig 2). These insights illuminate critical 242 pathways through which combined therapies modulate the immune landscape and enhance 243 treatment responses in pMMR/MSS/MSI-L mCRC.

244

245 Discussion:

By successfully reaching its main endpoint, this phase II trial shows that for combined Gamma Knife SBRT with tislelizumab greatly increases progression-free survival (PFS) in pMMR/MSS/MSI-L mCRC, resistant to first and second-line therapies. For this patient population, the combo treatment has shown both safety and tolerability. By overcoming resistance to first treatment plans, our study presents a creative therapy approach for those unresponsive to conventional treatments that offers a suitable therapeutic option improving clinical outcomes.

252

Among the several cancers including nasopharyngeal carcinoma, esophageal cancer, liver cancer, and lung cancer, Tislelizumab, a new PD-1 inhibitor, has been shown especially therapeutic efficacy. Combining tislelizumab with chemotherapy has essentially extended PFS in patients across these cancers (22-25).While immunotherapy has proven beneficial for some patients, metastatic colorectal

257 cancer (mCRC) presents unique challenges. Particularly in patients with MSS/pMMR tumors, which 258 are marked by low immunogenicity and great resistance to immunotherapy, tumor cells in mCRC 259 often evade immune detection and destruction (26). By directly targeting and destroying tumor cells, 260 Gamma Knife SBRT presents a potential solution by releasing a significant volume of tumor neoantigens, and improving tumor immunogenicity, so optimizing maximizing the efficacy of 261 262 subsequent immunotherapy(27). Furthermore demonstrated to extend survival in non-small cell lung 263 cancer (NSCLC) with patients with brain metastases is the combination of Gamma Knife SBRT and 264 immunotherapy (28). Still underreported, though, is the possibility of Gamma Knife SBRT coupled 265 with ICIs to improve the response in pMMR/MSS/MSI-L CRC.

266

267 In our clinical observations, a notable therapeutic effect was achieved in a patient treated with 268 combined SBRT and immunotherapy. We hypothesize that the addition of tislelizumab following 269 SBRT could extend progression-free survival (PFS) compared to either modality alone. Tumor 270 microenvironment post-radiotherapy showed significant changes revealed by sequencing analysis of 271 tumor samples 'both before and after combined treatment. More precisely, the microenvironment 272 transitioned from an immunosuppressive, angiogenesis- and fibrosis-promoting state to an 273 immune-enhanced, angiogenesis- and fibrosis-attenuated state. Comparatively to non-responders, 274 responders expressed genes linked to antigen presentation, tumor inflammation, and 275 immune-mediated tumor killing more strongly. Further showing the activation of several signaling 276 pathways associated with tumor cell death, including NF-kB, TNF, and JAK-STAT pathways was 277 enrichment analysis. Furthermore, immunotherapy targets such as PD-L1, showed an elevation, 278 which supports the possibility of efficient later immunotherapy. These findings substantiate our

hypothesis that patients with MSS-type mCRC resistant to first-line treatment could benefit significantly from the combination of stereotactic radiotherapy and immunotherapy, with enhanced immunogenicity and a more favorable tumor microenvironment facilitating improved therapeutic outcomes.

283

284 This trial restrictions even if its outcomes show promise. First of all, our results could be biased as a 285 single-arm study devoid of a control group. Second, the limited sample size and single-center design 286 of the study lower its statistical power hence more robust conclusions depend on bigger studies. 287 Furthermore, even though general survival (OS) was examined, the follow-up duration was insufficient to establish a reliable median OS. To address these limitations, a multi-center, 288 289 randomized controlled trial with a larger cohort and extended follow-up period is essential. This will 290 provide a more comprehensive evaluation of the efficacy and safety of combining Gamma Knife 291 SBRT and tislelizumab as a later-line therapy in pMMR/MSS/MSI-L mCRC patients.

292

Ultimately, for patients with pMMR/MSS/MSI-L mCRC who were unresponsive to first-line therapy regimens, the combination of Gamma Knife SBRT with tislelizumab demonstrated a high disease control rate (DCR) and manageable safety profile. Significant post-radiotherapy improvements in the tumor's suppressive immune microenvironment, reduced fibrosis, normalized tumor vasculature, and activation of the PD-1/PD-L1 checkpoint pathway revealed by biomarker analyses so improving the efficacy of immunotherapy.

299 Methods

Study design and participants

301 This single-arm, phase II trial was conducted at the First Affiliated Hospital of Jinan University to 302 assess the antitumor efficacy and safety of a combined regimen consisting of SBRT and tislelizumab 303 in patients with pMMR/MSS/MSI-L-type metastatic colorectal cancer (mCRC). The study is 304 registered with ClinicalTrials.gov (identifier: ChicTR2200011777). Eligible patients, aged 18-75 years, 305 had confirmed metastatic colorectal cancer. MSS and RAS mutation statuses were determined 306 through gene sequencing, while clinical staging was based on imaging examinations and 307 intraoperative findings. A total of 20 patients were enrolled in the study, with all providing written 308 informed consent. Detailed inclusion and exclusion criteria are available in the **Supplementary** 309 Materials.

310

311 **Procedures** :

312 As illustrated in Figure 1A, eligible patients received SBRT (administered 5-6 times per week, 3-5 Gy 313 per session) combined with tislelizumab (200 mg on day 1) was incorporated into the treatment 314 regimen. Each three-week cycle comprised a maximum of 12 cycles of induction therapy. Patients 315 achieving complete response (CR), partial response (PR), or stable disease (SD) transitioned to tislelizumab maintenance therapy (200 mg on day 1) until documented disease progression, death, 316 317 unacceptable toxicity, or patient withdrawal of consent. Treatment response was evaluated using CT 318 or MRI after each treatment cycle. Adverse events were systematically monitored and graded 319 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 320 5.0).

321

The study enrolled 20 eligible patients on November 24, 2022 (Figure 1B). All patients received at least one dose of the prescribed regimen. As of the data cutoff date (July 24, 2024), six patients continued to receive maintenance therapy. The median follow-up duration was 15 months (range: 3.4-20.0 months, IQR: 9.6-18.2 months). Due to disease-related complications, specimens could not be obtained from four patients, resulting in 16 patients being included in the per-protocol set (PPS).

327

328 Outcomes :

329 The primary endpoints of the study were objective response rate (ORR) and safety, encompassing 330 adverse events and serious adverse events, assessed according to RECIST version 1.1. Secondary 331 endpoints included disease control rate (DCR) and progression-free survival (PFS). ORR was 332 defined as the proportion of patients who achieved a best objective response of complete response 333 (CR) or partial response (PR) per RECIST criteria (version 1.1). DCR was defined as the proportion 334 of patients who achieved CR, PR, or stable disease (SD) according to RECIST criteria (version 1.1). 335 PFS was defined as the time from enrollment to the first documented disease progression per 336 RECIST version 1.1 or to death from any cause, whichever occurred first.

337

338 CD8 & PD-L1 expression level :

Tumoral CD8 & PD-L1 expression was measured by immunohistochemistry (IHC) (22C3 pharmDx 339 340 assays). The sections were scored for staining intensity according to the following scale: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown), and 3 (strong 341 342 staining, brown), with 0 and 1 considered low expression, and 2 and 3 considered high expression. 343 The score is divided into 4 levels according to the percentage of positive cells: 0%≤positive cell percentage ≤ 25%, 1 point; 25% < positive cell percentage ≤ 50%, 2 points; 50% < positive cell 344 345 percentage≤75%, 3 points; 75%<positive cell percentage≤100%, 4 points. IHC score = cell staining intensity score x positive cell percentage score. The PD-L1 combined positive score (CPS) was 346 defined as the number of PD-L1 positive cells (tumor cells, lymphocytes, macrophages) as a 347 348 proportion of the total number of tumor cells multiplied by 100. Positive PD-L1 expression was considered when the CPS was >1. 349

350

351 Nanostring panel RNA sequencing :

Due to disease-related limitations, specimens could not be obtained from four patients, resulting in a cohort of 16 patients for combined analysis. Tumor tissue samples were collected both before treatment (BT) and after treatment (AT). Gene expression of each sample was measured using the

355 NanoString nCounter platform (NanoString Technologies, Seattle, WA). The quantitative 356 transcriptome data were obtained based on the 289-immuno-gene panel, which includes 289 genes 357 related to the tumor, tumor microenvironment, and immune responses in cancer. The samples that 358 passed the quality control (QC), which included Imaging QC, Binding Density QC, Positive Control 359 Linearity QC, and Positive Normalization QC can be processed in further analysis. The raw count 360 data of 289 genes were normalized using the R package NanoStringNorm according to the 361 geometric mean of five housekeeping genes. The log2 transformation was then performed on the 362 normalized data. Differentially expressed genes were identified using the "DEseq2" package, 363 employing criteria of log2[fold change] > 1 and false discovery rate < 0.05. Heatmaps depicting the expression patterns of these differentially expressed genes were generated using the 364 365 "ComplexHeatmap" package.

366

367 Immune cell profile analyses and Additional immune signatures analysis

The determination of immune cell types and gene sets associated with immunotherapy response was informed by established literature sources (29,30). We transformed each attribute (immune signature or gene set) value (GSVA score) xi into xi ' by the equation xi ' = (xi = -xmin)/(xmax = -xmin), where xmin and xmax represent the minimum and maximum of the ssGSEA scores for the gene set across all samples, respectively. The detailed gene signature list can be found in the **Supplementary Table**.

374

375 Gene set enrichment and pathway analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG) / Gene Ontology (GO) enrichment analysis was performed using the Clusterprofiler R package. The list of gene IDs was used as the input file. The Benjamini-Hochberg method was employed to adjust the p-values. The cut-off threshold of p-values was set to 0.05. The enrichment results were visualized by the ggplot2 R package. The enrichment statistic was set to classic.

381

382 Statistical analyses

Progression-free survival (PFS) and OS was estimated utilizing the Kaplan-Meier method. Statistical analyses were conducted using R (version 3.6.1). Differences between subgroups in terms of efficacy response were assessed using the nonparametric Wilcoxon rank-sum test (Mann-Whitney U test), while comparisons between pre- and post-treatment samples were analyzed with the Wilcoxon signed-rank test. Confidence intervals (CIs) for response rates were calculated employing the Clopper-Pearson method, with all reported P values being two-sided. A P value < 0.05 was considered statistically significant.

390

391 **Data availability**

The data generated in this study are available within the article and its **Supplementary Data**. Additional data or resources related to this article are available upon reasonable request from the corresponding authors.

395

396 Acknowledgments

397 This research was supported by the Clinical Frontier Technology Program of the First Affiliated

Hospital of Jinan University (No. JNU1AF-CFTP-2022-a01223), the National Natural Science

Foundation of China (82204436), Natural Science Foundation of Guangdong Province

400 (2024A1515030010, 2022A1515011695), Science and Technology Projects in Guangzhou

401 (2024A03J0825).

402

403 Ethics approval and consent to participate

404 This trail was conducted in accordance with the Declaration of Helsinki after approval by the

Institutional Review Board of The First Affiliated Hospital of Jinan University (KY-2022-236). All

406 patients provided written informed consent. The ClinicalTrials.gov identifier was:

407 ChiCTR2200066117.

408

409 Author Contributions

Y Zhang, H Guan and S Liu: acquisition of data, analysis of experimental data and drafted the manuscript. H Li and Z Bian: Investigation, visualization and methodology. J He, Z Zhao and S Qiu: data curation, software and formal analysis. T Mo, X Zhang and Z Chen: technical expertise inmanuscript editing. H Ding and X Zhao: assay optimization, acquisition, and analysis and interpretation of histology and pathology. L Wang, Y Pan and J Pan: funding acquisition, designed the study and writing-review and editing the draft.

417 References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020:
 GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer
 journal for clinicians 2021;71(3):209-49 doi 10.3322/caac.21660.
- 421 2. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, *et al.* Colorectal cancer statistics,
 422 2020. CA: a cancer journal for clinicians **2020**;70(3):145-64 doi 10.3322/caac.21601.
- 423 3. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. Jama
 424 2021;325(7):669-85 doi 10.1001/jama.2021.0106.
- 4254.Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology426(CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chinese journal of427cancer research = Chung-kuo yen cheng yen chiu **2019**;31(1):117-34 doi 10.21147/j.issn.1000-9604.2019.01.07.
- Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, *et al.* Colon Cancer, Version 2.2021,
 NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN
 2021;19(3):329-59 doi 10.6004/jnccn.2021.0012.
- 431 6. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nature
 432 reviews Drug discovery 2014;13(11):828-51 doi 10.1038/nrd4389.
- Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, *et al.* Outcome according to
 KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in
 metastatic colorectal cancer by the AIO colorectal cancer study group. Annals of oncology : official journal of
 the European Society for Medical Oncology 2016;27(9):1746-53 doi 10.1093/annonc/mdw261.
- 437 8. Asaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal
 438 of medicine 2015;373(20):1979 doi 10.1056/NEJMc1510353.
- 439 9. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer:
 440 rationale, challenges and potential. Nature reviews Gastroenterology & hepatology 2019;16(6):361-75 doi
 441 10.1038/s41575-019-0126-x.
- 44210.Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances443and future directions. Molecular cancer 2022;21(1):28 doi 10.1186/s12943-021-01489-2.
- Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, *et al.* Accumulation of MDSC and Th17
 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug
 Treatment Regimen. Cancer research 2016;76(18):5241-52 doi 10.1158/0008-5472.Can-15-3164.
- Hamid MA, Pammer LM, Lentner TK, Doleschal B, Gruber R, Kocher F, et al. Immunotherapy for
 Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
 Current oncology reports 2024 doi 10.1007/s11912-024-01583-w.
- 45013.Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, et al. Upfront FOLFOXIRI plus451bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer452(AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology453**2022**;23(7):876-87 doi 10.1016/s1470-2045(22)00274-1.
- 454 14. Papiez L, Timmerman R, DesRosiers C, Randall M. Extracranial stereotactic radioablation: physical principles.
 455 Acta oncologica (Stockholm, Sweden) 2003;42(8):882-94 doi 10.1080/02841860310013490.
- 45615.Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and457thrombocytopenia: analysis of risk factors and development of a predictive model. Blood 1997;89(7):2303-10.
- 45816.Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, et al. A Pilot Study of Stereotactic Body Radiation459Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical cancer460research : an official journal of the American Association for Cancer Research 2017;23(17):5055-65 doi

| 461 | | 10.1158/1078-0432.Ccr-16-2946. |
|-----|-----|---|
| 462 | 17. | Choi CW, Jeong MH, Park YS, Son CH, Lee HR, Koh EK. Combination Treatment of Stereotactic Body Radiation |
| 463 | | Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects. Cancer |
| 464 | | research and treatment 2019 ;51(2):464-73 doi 10.4143/crt.2018.186. |
| 465 | 18. | Morinaga N, Tanaka N, Shitara Y, Ishizaki M, Yoshida T, Kouga H, et al. Ten-Year Survival of a Patient Treated with |
| 466 | | Stereotactic Gamma Knife Radiosurgery for Brain Metastases from Colon Cancer with Ovarian and Lymph Node |
| 467 | | Metastases: A Case Report. Case reports in gastroenterology 2016 ;10(1):199-206 doi 10.1159/000445976. |
| 468 | 19. | Liu S, Zhang Y, Lin Y, Wang P, Pan Y. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed |
| 469 | | systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy. Frontiers in |
| 470 | | immunology 2022 ;13:981527 doi 10.3389/fimmu.2022.981527. |
| 471 | 20. | Herzog BH, Baer JM, Borcherding N, Kingston NL, Belle JI, Knolhoff BL, et al. Tumor-associated fibrosis impairs |
| 472 | | immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Science |
| 473 | | translational medicine 2023 ;15(699):eadh8005 doi 10.1126/scitranslmed.adh8005. |
| 474 | 21. | Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, et al. Hypoxia as a driver |
| 475 | | of resistance to immunotherapy. Drug resistance updates : reviews and commentaries in antimicrobial and |
| 476 | | anticancer chemotherapy 2021 ;59:100787 doi 10.1016/j.drup.2021.100787. |
| 477 | 22. | Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for |
| 478 | | recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer cell |
| 479 | | 2023 ;41(6):1061-72.e4 doi 10.1016/j.ccell.2023.04.014. |
| 480 | 23. | Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as |
| 481 | | First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. |
| 482 | | JAMA oncology 2021 ;7(5):709-17 doi 10.1001/jamaoncol.2021.0366. |
| 483 | 24. | Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, et al. Tislelizumab Versus Chemotherapy as Second-Line |
| 484 | | Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized |
| 485 | | Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| 486 | | 2022 ;40(26):3065-76 doi 10.1200/jco.21.01926. |
| 487 | 25. | Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al. Tislelizumab vs Sorafenib as First-Line Treatment for |
| 488 | | Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA oncology |
| 489 | | 2023 ;9(12):1651-9 doi 10.1001/jamaoncol.2023.4003. |
| 490 | 26. | Zhao W, Jin L, Chen P, Li D, Gao W, Dong G. Colorectal cancer immunotherapy-Recent progress and future |
| 491 | | directions. Cancer letters 2022 ;545:215816 doi 10.1016/j.canlet.2022.215816. |
| 492 | 27. | Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, et al. Safety |
| 493 | | and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in |
| 494 | | advanced non-small cell lung cancer, the phase SICI trial. Lung cancer (Amsterdam, Netherlands) |
| 495 | | 2023 ;178:96-102 doi 10.1016/j.lungcan.2023.02.004. |
| 496 | 28. | Cho A, Untersteiner H, Hirschmann D, Shaltout A, Göbl P, Dorfer C, et al. Gamma Knife Radiosurgery for Brain |
| 497 | | Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. Cancers |
| 498 | | 2020 ;12(12) doi 10.3390/cancers12123668. |
| 499 | 29. | He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic |
| 500 | | profiling. Journal of experimental & clinical cancer research : CR 2018 ;37(1):327 doi |
| 501 | | 10.1186/s13046-018-1002-1. |
| 502 | 30. | Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, et al. Clinical and biomarker analyses of sintilimab plus |
| 503 | | gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nature |
| 504 | | communications 2023 ;14(1):1340 doi 10.1038/s41467-023-37030-w. |

505 Figure legends

Α

В



506

507 Figure 1. Clinical trial flow chart. A) Flowchart of therapeutic regimen. B) Flow diagram of participants in the

508 study.





Figure 2. Clinical trial results. A) Swimmer plots of patients. B) Kaplan–Meier curves of OS for the
per-protocol set (N = 20). C) Kaplan–Meier curves of PFS for the per-protocol set (N = 20). D) Kaplan–Meier
curves of PFS for didn't receive immunotherapy set (control group) (N= 23) and per-protocol set (test group)
(N=20). E) Radiological response from patient. F) Waterfall plot of best percent change from baseline in patient
target lesion (N= 20). G) Waterfall plot of best percent change from baseline in patient off-target lesion (N= 12).





Figure 3. Differential expressed genes analysis. A) Specimens collection flowchart. **B)** Transcriptome analysis on differential expression genes before and after treatment between responders (PR) (n = 9) and non-responders (Non-PR) (n = 7), DESeq2 was provided to perform differential expression testing. **C)** The abundance of predefined 12 immune cells composition before and after treatment between responders (PR) (n = 9) and = 9) and non-responders (Non-PR) (n = 7), Wilcoxon test was used to determine the statistical significance between subgroups. **D)** Radiological response from patient. **E)** Representative CD8 & PD-L1 IHC staining of before and after treatment specimens of patient.



523

Figure 4. Additional immune signatures analysis. A) The expression of 12 gene sets previously reported to be associated with response to immunotherapy and prognosis between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14). **BCD**) 11 gene sets of prognostic value were differentially expressed between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14), box plots are indicated in terms of minima, maxima, centre, bounds of box and whiskers (interquartile range value), and percentile in the style of Tukey, Wilcoxon test was used to determine the statistical significance between subgroups.





А

Pathway



539

540 Supplementary Figure1. GO enrichment and KEGG pathways analysis of differential expression genes. 541 A) GO enrichment analysis were performed to identify the biological process, cellular component and 542 molecular function of differential expression genes. B) H KEGG enrichment analysis of differential expression 543 genes.



545 Supplementary Figure2. Comparison of non-responders before and after treatment.